Indatraline
| Indatraline | |
|---|---|
| Indatraline.png | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 100316-43-5 |
| PubChem | 3033964 |
| DrugBank | |
| ChemSpider | 2298530 |
| KEGG | D04495 |
Indatraline is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that was originally developed for the treatment of depression and other mood disorders. It is known for its ability to inhibit the reuptake of the three major monoamine neurotransmitters: serotonin, norepinephrine, and dopamine.
Pharmacology[edit]
Indatraline functions by blocking the reuptake of serotonin, norepinephrine, and dopamine, thereby increasing the levels of these neurotransmitters in the synaptic cleft and enhancing their activity in the central nervous system. This mechanism of action is similar to that of other SNDRIs, such as cocaine and methylphenidate, but indatraline is not commonly used due to its potential for abuse and side effects.
Chemical Structure[edit]
The chemical structure of indatraline is characterized by a tetrahydronaphthalene core with a dichlorophenyl group and a dipropylamine side chain. The IUPAC name for indatraline is (1R,2S)-2-(3,4-dichlorophenyl)-1-methyl-N,N-dipropyl-1,2,3,4-tetrahydronaphthalen-1-amine.
Clinical Use[edit]
Indatraline was initially investigated for its potential use in treating depression and other mood disorders. However, due to its potent effects on the reuptake of multiple neurotransmitters and the associated risk of side effects, it has not been widely adopted in clinical practice. Research into its use has largely been overshadowed by the development of other antidepressants with more favorable safety profiles.
Side Effects[edit]
The side effects of indatraline are similar to those of other SNDRIs and can include insomnia, anxiety, nausea, and increased heart rate. Due to its potent action on multiple neurotransmitter systems, there is also a risk of serotonin syndrome and other serious adverse effects.
Research[edit]
Despite its limited clinical use, indatraline continues to be of interest in research settings. Studies have explored its potential applications in treating substance use disorders and its effects on neurotransmitter systems.
See Also[edit]
- Serotonin-norepinephrine-dopamine reuptake inhibitor
- Monoamine neurotransmitter
- Depression
- Serotonin
- Norepinephrine
- Dopamine
 | This medical article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
